Albireo Pharma (FRA:BDQM) Marketable Securities : €0.00 Mil (As of Sep. 2022)

View and export this data going back to 2007. Start your Free Trial

What is Albireo Pharma Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Albireo Pharma's Marketable Securities for the quarter that ended in Sep. 2022 was €0.00 Mil.

Albireo Pharma Marketable Securities Historical Data

The historical data trend for Albireo Pharma's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albireo Pharma Marketable Securities Chart

Albireo Pharma Annual Data

Trend

Sep12

Sep13

Sep14

Sep15

Sep16

Dec17

Dec18

Dec19

Dec20

Dec21

Marketable Securities

Get a 7-Day Free Trial

Albireo Pharma Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Marketable Securities	Get a 7-Day Free Trial															-	-	-	-	-

Albireo Pharma Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Albireo Pharma (FRA:BDQM) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Albireo Pharma Marketable Securities Related Terms

Thank you for viewing the detailed overview of Albireo Pharma's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Albireo Pharma (FRA:BDQM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albireo Pharma Inc (FRA:BDQM) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

53 State Street, 19th Floor, Boston, MA, USA, 02109

Website

https://www.albireopharma.com

Albireo Pharma Inc is a commercial-stage biopharmaceutical company. It focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. The Company's product pipeline includes Bylvay, which is approved in the United States and Europe; elobixibat, which is approved in Japan for the treatment of chronic constipation; A3907, its Phase 1 lead candidate for the treatment of adult liver diseases; and A2342, it's a lead preclinical candidate for the treatment of adult viral and liver diseases.

Albireo Pharma (FRA:BDQM) Headlines

No Headlines